



ALBEGA Medical

High-end radio-ligand diagnostics and therapeutics

Non-confidential company presentation

ALBEGA – Business



Theranostic Radiopharmaceuticals in Oncology

Therapy

- Total eradication
- Overcome therapy resistance

Diagnostics

- Very early disease detection

Attractive Market Environment for Radiopharmaceuticals

Novartis – AAA & Endocyte:
€3 bn deal

Merger of IBA Molecular and Mallinckrodt to Curium

In-licensing deal 3B Pharmaceutical by Ipsen

1st Pipeline Compound

Tetrofosmin (TTF)

Late stage (phase III) Glioma diagnostic


Early stage Glioma therapeutic research

Late stage myocard generic

ALBEGA – In a nutshell



1st Compound → 3 Applications




Glioma – brain tumor with high medical need

- ~70% of the patients die within 1 year
- Trusty differential glioma imaging
- Efficient glioma therapy

ALBEGA – Achievements



Current investment € 4.7 mio (pre-series A)



ALBEGA – Financials



Innovative Differential Glioma Diagnostic

- Market exclusivity
- Ready to start Phase III
- Launch in 2023
- Financial need € 3 mio
- First revenues in 2023
 - Cumulative 5-year > € 15 mio (EU)

GLIOTECT



Innovative Glioma Therapy

- Complementary novel therapeutic opportunity
- Early stage
- Financial need € 2.5 mio up to clinical study start
- First revenues after 2025 in a multi-mio market

GLIOTHER



Generic to Myoview, a blockbuster radio-pharmaceutical of the 2000s

- Close-to-market
- Launch in 2021
- Financial need € 0.5 mio
- First revenues in 2021
 - Cumulative 5-year > € 80 mio globally

MYOTECT




Enter nuclear medicine diagnostic and therapy market with a thrilling, cost-efficient package based on proven TTF technology with unrivalled proven safety and reliability

ALBEGA – Building a pipeline



Combining conventional Pharma Development
with the Power of Nuclear Medicine



ALBEGA – Team



Dr. Christian Wunsch
(CEO, Co-Founder)

cwunsch@albega-medical.com
+49 (0) 30 77 20 59 2-14

Dr. Daniel Schubart
(COO, Co-Founder)

schubart@albega-medical.com
+49 (0) 30 77 20 59 2-21

International network of
supporting companies,
medical experts and advisors

- ✓ Manufacturing
- ✓ Clinical operations
- ✓ Regulatory support



Horizon 2020 – SME Instrument (Phase 2)

*Validation of blood-brain-barrier permeability as a glioma biomarker
by means of the radiotracer ^{99m}Tc -tetrofosmin (TTF)
and single-photon emission computed tomography (SPECT)''*

*This project receives funding of €4.7 mio from the European Union's
Horizon 2020 research and innovation programme, GA 673737*

c/o ConsulTech GmbH | Morgensternstraße 24 | D-12207 Berlin | www.consultech.de